Cempra Inc CEMP:NASDAQ (Common Stock)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 12.61 | -0.05 -0.39% | 405,022 | 525.5K |
Latest News Headlines for Cempra Inc
Latest Annual and Quarterly SEC Filings
More FilingsCompany Background
Cempra, Inc., formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Its program CEM-101 is developing in both oral and intravenous (IV), formulations initially for the treatment of community-acquired bacterial pneumonia (CABP). Its second program is Taksta, which is developing in the United States as an oral treatment for bacterial infections caused by Staphylococcus aureus (S. Aureus), including methicillin-resistant S. aureus (MRSA). As of January 30, 2012, the Company completed a Phase II clinical trial in, which the oral formulation of CEM-101 demonstrated comparable efficacy to the levofloxacin. As of January 30, 2012, its second program Taksta has completed a Phase II clinical trial in patients.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 12.64 |
| Previous Close | 12.61 |
| Day High | -- |
| Day Low | -- |
| 52 Week High | 1/22/2014 | 15.39 |
| 52 Week Low | 4/15/2014 | 8.10 |
| % Off 52 Week High | -18.06% |
| % Off 52 Week Low | 55.68% |
| Beta (5 Yr) | -- |
| Volatility Avg | 10/8/2014 | 51.14 |
| 10-Day Avg. Volume | 525,509 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | -1.92 |
|---|---|
| P/E Ratio | 6/30/2014 | -- |
| Market Cap | Small Cap | 419M |
| Shares Outstanding | 33.24M |
| Float | 31.1M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | -- |
|---|---|
| Ex-Date | -- |
| Dividend Announcement | -- |
| Date of Record | -- |
| Payable | -- - -- |
| Payable Date | -- |
Peers Information HelpCEMP Cempra Inc vs. Peers
| Peers | |
|---|---|
CEMP Cempra Inc | 1.78% |
Johnson & Johnson | 14.54% |
Pfizer Inc. | -4.08% |
Abbott Laboratories | 9.94% |
Cubist Pharmaceuticals Inc | -5.05% |
CEMP Cempra Inc | 0.00% |
Johnson & Johnson | 2.67% |
Pfizer Inc. | 3.54% |
Abbott Laboratories | 2.09% |
Cubist Pharmaceuticals Inc | -- |
CEMP Cempra Inc | -0.39% |
Johnson & Johnson | 2.46% |
Pfizer Inc. | 2.05% |
Abbott Laboratories | 1.64% |
Cubist Pharmaceuticals Inc | 2.33% |